Related Experiment Video

Updated: Jan 30, 2026

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice
07:28

Real-time Pressure-volume Analysis of Acute Myocardial Infarction in Mice

Published on: July 2, 2018

9.6K

Beta-blocker use in patients with acute myocardial infarction treated by hospitalists

L Dall1, T Simmons, S Peterson

  • 1Midwest Hospital Specialists, Kansas City, Missouri, USA.

Managed Care Interface
|November 7, 2000
PubMed

Insights

Beta blocker use after myocardial infarction significantly increased in a hospitalist group after education and implementing a uniform discharge summary. This improved prescribing of life-saving medications for heart attack patients.

Area of Science:

  • Cardiology
  • Healthcare Quality Improvement

Background:

  • Beta blockers are proven to improve survival in patients post-myocardial infarction.
  • Current beta blocker utilization rates in post-myocardial infarction patients require optimization.

Purpose of the Study:

  • To assess and enhance beta blocker prescribing practices within a large hospitalist group for patients with myocardial infarction.
  • To identify factors influencing beta blocker administration and implement targeted interventions.

Main Methods:

  • Retrospective cohort analysis of beta blocker use in myocardial infarction patients.
  • Educational intervention and implementation of a uniform discharge summary.
  • Prospective data collection to evaluate the impact of interventions.

Main Results:

  • Initial retrospective beta blocker use was 68%, significantly lower than comparative cohorts (21%, 34%).
  • Following data review and education, prospective beta blocker use increased to 90%.
  • Statistical analysis confirmed significant improvements in beta blocker administration (P < .0005).

Conclusions:

  • A focused educational initiative and standardized discharge summary significantly improved beta blocker prescribing rates.
  • Optimizing clinical practice through data feedback and targeted interventions enhances the use of evidence-based therapies.
  • Hospitalist group adherence to beta blocker guidelines for myocardial infarction patients was substantially enhanced.

More Related Videos

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K
Acute Myocardial Infarction in Rats07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

54.6K

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
598
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.8K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
796
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.6K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.7K